These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 12789723)

  • 1. Sanazole as a sensitizer of hypoxic cells with radical radiation in the treatment of advanced cancer of cervix an Indian experience.
    Huilgol NG; Dobrowsky W; Tatsuzaki H; Chatterjee NA; Kagiya VT; Das K
    Indian J Cancer; 2002 Jun; 39(2):39-44. PubMed ID: 12789723
    [TBL] [Abstract][Full Text] [Related]  

  • 2. AK-2123 (Sanazol) as a radiation sensitizer in the treatment of stage III cervical cancer: results of an IAEA multicentre randomised trial.
    Dobrowsky W; Huigol NG; Jayatilake RS; Kizilbash NI; Okkan S; Kagiya VT; Tatsuzaki H
    Radiother Oncol; 2007 Jan; 82(1):24-9. PubMed ID: 17161478
    [TBL] [Abstract][Full Text] [Related]  

  • 3. AK-2123 (Sanazol) as a radiation sensitizer in the treatment of stage III cancer cervix: initial results of an IAEA multicentre randomized trial.
    Dobrowsky W; Huigol NG; Jayatilake RS; Kizilbash NI; Okkan S; Kagiya TV; Tatsuzaki H
    J Cancer Res Ther; 2005; 1(2):75-8. PubMed ID: 17998631
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Results of a phase II trial of concurrent chemoradiation in the treatment of locally advanced carcinoma of uterine cervix: an experience from India.
    Saibishkumar EP; Patel FD; Sharma SC
    Bull Cancer; 2005 Jan; 92(1):E7-12. PubMed ID: 15811845
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical impact of MRI assisted dose volume adaptation and dose escalation in brachytherapy of locally advanced cervix cancer.
    Pötter R; Dimopoulos J; Georg P; Lang S; Waldhäusl C; Wachter-Gerstner N; Weitmann H; Reinthaller A; Knocke TH; Wachter S; Kirisits C
    Radiother Oncol; 2007 May; 83(2):148-55. PubMed ID: 17531904
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Concurrent weekly cisplatin and radiotherapy in routine management of cervical cancer: a report on patient compliance and acute toxicity.
    Serkies K; Jassem J
    Int J Radiat Oncol Biol Phys; 2004 Nov; 60(3):814-21. PubMed ID: 15465198
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase III randomized study of misonidazole plus radiation vs. radiation alone for cervix cancer.
    Chan P; Milosevic M; Fyles A; Carson J; Pintilie M; Rauth M; Thomas G
    Radiother Oncol; 2004 Mar; 70(3):295-9. PubMed ID: 15064016
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regional hyperthermia combined with radiotherapy for uterine cervical cancers: a multi-institutional prospective randomized trial of the international atomic energy agency.
    Vasanthan A; Mitsumori M; Park JH; Zhi-Fan Z; Yu-Bin Z; Oliynychenko P; Tatsuzaki H; Tanaka Y; Hiraoka M
    Int J Radiat Oncol Biol Phys; 2005 Jan; 61(1):145-53. PubMed ID: 15629605
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Concurrent weekly cisplatin plus external beam radiotherapy and high-dose rate brachytherapy for advanced cervical cancer: a control cohort comparison with radiation alone on treatment outcome and complications.
    Chen SW; Liang JA; Hung YC; Yeh LS; Chang WC; Lin WC; Yang SN; Lin FJ
    Int J Radiat Oncol Biol Phys; 2006 Dec; 66(5):1370-7. PubMed ID: 16979836
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of overall treatment time and radiobiological parameters on biologically effective doses in cervical cancer patients treated with radiation therapy alone.
    Gasinska A; Fowler JF; Lind BK; Urbanski K
    Acta Oncol; 2004; 43(7):657-66. PubMed ID: 15545186
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I clinical trial of weekly paclitaxel, weekly carboplatin, and concurrent radiotherapy for primary cervical cancer.
    Rao GG; Rogers P; Drake RD; Nguyen P; Coleman RL
    Gynecol Oncol; 2005 Jan; 96(1):168-72. PubMed ID: 15589596
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Concomitant chemobrachyradiotherapy with ifosfamide and cisplatin followed by consolidation chemotherapy in locally advanced squamous cell carcinoma of the uterine cervix: results of a phase II study.
    Vrdoljak E; Prskalo T; Omrcen T; Situm K; Boraska T; Frleta Ilić N; Janković S; Hamm W
    Int J Radiat Oncol Biol Phys; 2005 Mar; 61(3):824-9. PubMed ID: 15708262
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Extended-field radiotherapy and high-dose-rate brachytherapy with concurrent and adjuvant cisplatin-based chemotherapy for locally advanced cervical cancer: a phase I/II study.
    Chung YL; Jian JJ; Cheng SH; Hsieh CI; Tan TD; Chang HJ; Hung CF; Horng CF; Soong T; Tsou MH
    Gynecol Oncol; 2005 Apr; 97(1):126-35. PubMed ID: 15790448
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment of chlorpromazine as radiation sensitizer and protector.
    Huilgol NG; Chatterjee N; Singh BB
    Indian J Cancer; 1996 Dec; 33(4):195-200. PubMed ID: 9255000
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preoperative hyperfractionated chemoradiation for locally recurrent rectal cancer in patients previously irradiated to the pelvis: A multicentric phase II study.
    Valentini V; Morganti AG; Gambacorta MA; Mohiuddin M; Doglietto GB; Coco C; De Paoli A; Rossi C; Di Russo A; Valvo F; Bolzicco G; Dalla Palma M;
    Int J Radiat Oncol Biol Phys; 2006 Mar; 64(4):1129-39. PubMed ID: 16414206
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Feasibility trial for daily oral administration of the hypoxic sensitizer AK-2123 (Sanazole) in radiotherapy.
    Yamazaki H; Nakamura S; Kobayashi K; Tsubokura T; Kodani N; Aibe N; Yoshida K; Kagiya T; Koizumi M; Yamada K
    Anticancer Res; 2013 Feb; 33(2):643-6. PubMed ID: 23393361
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A retrospective review of 15 years of radical radiotherapy with or without concurrent cisplatin and/or 5-fluorouracil for the treatment of locally advanced cervical cancer.
    Borowsky ME; Elliott KS; Pezzullo JC; Santoso P; Choi W; Choi K; Abulafia O
    Bull Cancer; 2005 Feb; 92(2):E19-24. PubMed ID: 15749639
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High-dose-rate brachytherapy in uterine cervical carcinoma.
    Patel FD; Rai B; Mallick I; Sharma SC
    Int J Radiat Oncol Biol Phys; 2005 May; 62(1):125-30. PubMed ID: 15850912
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Five years' experience treating locally advanced cervical cancer with concurrent chemoradiotherapy and high-dose-rate brachytherapy: results from a single institution.
    Parker K; Gallop-Evans E; Hanna L; Adams M
    Int J Radiat Oncol Biol Phys; 2009 May; 74(1):140-6. PubMed ID: 18922646
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low-dose-rate vs. high-dose-rate intracavitary brachytherapy for carcinoma of the cervix: The University of Alabama at Birmingham (UAB) experience.
    Falkenberg E; Kim RY; Meleth S; De Los Santos J; Spencer S
    Brachytherapy; 2006; 5(1):49-55. PubMed ID: 16563997
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.